Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 4, 2006, Pages 402-408

  Shin, Sonya S ^a,b,c   Pasechnikov, A D ^c   Gelmanova, I Y ^c   Peremitin, G G ^d   Strelis, A K ^e,f   Andreev, Y G ^g   Golubchikova, V T ^d   Tonkel, T P ^d   Yanova, G V ^f   Nikiforov, M ^c   Yedilbayev, A ^c   Mukherjee, J S ^a,b,c   Furin, J J ^a,b,c   Barry, D J ^a   Farmer, P E ^a,b,c   Rich, M L ^a,c   Keshavjee, S ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS IN HEALTH   (United States)

^d Tomsk Oblast Tuberculosis Services   (Russian Federation)

^e SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^f Tomsk Oblast Clinical Tuberculosis Hospital   (Russian Federation)

^g Ministry of Justice   (Russian Federation)

Author keywords

Alcohol; DOTS Plus; Multidrug resistant tuberculosis; Russia

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG FATALITY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PRISON; RUSSIAN FEDERATION; TREATMENT FAILURE; TREATMENT OUTCOME; USSR;

EID: 33645654518     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Coker R. Control of tuberculosis in Russia. Lancet 2001; 358: 434-435.
2. Farmer P E, Kononets A S, Borixov S E, Goldfarb A, Healing T, Mckee M. Recrudescent tuberculosis in the Russian Federation. Harvard Medical School and Open Society Institute. The global impact of drug resistant tuberculosis. Boston, MA: Program in Infectious Disease and Social Change, 1999: 39-83.
3. Pablos-Mendez A, Raviglione M, Laszlo A, et al. for the World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
4. Erratum in: N England J Med 1998; 339: 139.
5. Kimerling M E, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3: 451-453.
6. Lafontaine D, Slavuski A, Vazhnina N, Sheyanenko O. Treatment of multidrug-resistant tuberculosis in Russian prisons. Lancet 2004; 363: 246-247.
7. Kimerling M E, Slavuckij A, Chavers S, et al. The risk of MDR-TB and polyresistant tuberculosis among the civilian population of Tomsk city, Siberia, 1999. Int J Tuberc Lung Dis 2003; 7: 866-872.
8. Ruohonen R, Goloubeva T, Trnka L, et al. Implementation of the DOTS strategy for tuberculosis in the Leningrad Region, Russian Federation (1998-1999). Int J Tuberc Lung Dis 2002; 6: 192-197.
9. Espinal M, Kim S, Suarez P, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
10. Mawer C, Ignatenko N, Wares D, et al. Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, Western Siberia. Lancet 2001; 358: 434-435.
11. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of MDR-TB. In: Gupta R, Arnadottir T, eds. WHO/CDS/TB/2000.279. Geneva, Switzerland: WHO, 2000.
12. World Health Organization/International Union Against Tuberculosis and Lung Disease. Global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world-Report No. 2, Prevalence and Trends. WHO/CDS/TB/2000.278. Geneva, Switzerland: WHO, 2000.
13. Kent P, Kubica G. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: Centers for Disease Control, 1985.
14. Heifets L. Drug susceptibility testing. Clin Lab Med 1996; 16: 641-656.
15. Mukherjee J, Rich M, Socci A, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
16. Keshavjee S, Gelmanova I, Peremitin I, et al. Using DOTS-Plus to improve DOTS and expand access to effective tuberculosis treatment in Tomsk Oblast, Russia. Presented at the 35th World Conference on Lung Health & 5th DOTS Expansion Working Group Meeting; Oct 28-Nov 1, 2004; Paris, France. Int J Tuberc Lung Dis 2004; 11 (Suppl 1): 9138.
17. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
18. Laserson K, Thorpe L, Lemaine V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
19. Coninx R, Pfyffer G, Mathieu C, et al. Drug resistant tuberculosis in prisons in Azerbaijan: a case study. BMJ 1998; 316: 1423-1425.
20. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
21. Neville K, Bromberg A, Bromberg R, Bonk S, Hanna B, Rom W. The third epidemic-multidrug-resistant tuberculosis. Chest 1994; 105: 45-48.
22. Tahaoǧlu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
23. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
24. Chan E, Laurel V, Strand M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
25. Suarez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
26. Leimane V, Riekstina V, Holtz T, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
27. Dewan P, Arguin P, Kiryanova H, et al. Risk factors for death during tuberculosis treatment in Orel, Russia. Int J Tuberc Lung Dis 2004; 8: 598-602.
28. Zafran N, Heldal E, Pavlovic S, Vuckovic D, Boe J. Why do our patients die of active tuberculosis in the era of effective therapy? Tubercle Lung Dis 1994; 75: 329-333.
29. White M C, Portillo C J. Tuberculosis mortality associated with AIDS and drug or alcohol abuse: analysis of multiple cause-of-death data. Public Health 1996; 110: 185-189.
30. Santha T, Garg R, Frieden T R, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002; 6: 780-788.
31. Maher D, Gupta R, Uplekar M, Dye C, Raviglione M. Directly observed therapy and treatment adherence. Lancet 2000; 356: 1031-1032.
32. Farmer P, Robin S, Ramilus S L, Kim J Y. Tuberculosis, poverty, and 'compliance': lessons from rural Haiti. Semin Respir Infect 1991; 6: 254-260.
33. Jakubowiak W. Social support for patients: evidence from experience in the Russian Federation. In: 36th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Paris, France, October 2005.
34. Sweetkand A, Acha D, Guerra D. Enhancing adherence: the role of group psychotherapy in the treatment of MDR-TB in urban Peru. In: Cohen A, Kleinman A, Saraceno B, eds. World Mental Health Casebook: Social and Mental Health Interventions in Low-Income Countries. New York, NY: Kluwer Academic/Plenum Press, 2002: pp 51-79.